GLPwatch
Papers (12034)
Page 193 of 201, ranked by citation count.
- THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty.
- Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.
- The central amygdala gates exogenous glucagon-like peptide 1 signals.
- Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
- Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study.
- An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin.
- Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
- Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL.
- Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy.
- GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials.
- In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.
- Tirzepatide improves extracellular matrix integrity and vascularization in pancreatic islets of a mouse model of obesity, diabetes, and menopause.
- Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker-256 tumour-bearing rats.
- Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study.
- [Liraglutide for weight loss in overweight and obese adults].
- Integrative proteogenomic analyses implicate KLK13 as a glycaemia-linked circulating protein in diabetic kidney disease.
- Efficacy and tolerance of GLP-1 analogues in the treatment of adolescent obesity: analysis of a French population.
- Development of a Follow-Up Protocol for Patients Treated with Injectable Semaglutide for Weight Loss: Design of a Research Study in Community Pharmacy.
- Retrospective Study on the Efficacy and Safety of Dulaglutide in Patients with Diabetes and Moderate-Advanced Chronic Kidney Disease.
- Unraveling the safety and efficacy of semaglutide for people living with HIV and metabolic co-morbidities.
- Reply to "Eligibility for and practical implications of semaglutide in overweight and obese patients with acute coronary syndrome, a letter to editor".
- Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).
- Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.
- Correction to: Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
- Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).
- Frailty and Semaglutide in Obesity-Related HFpEF: Another STEP in the Right Direction.
- Association of oral semaglutide with cardiovascular outcomes in a real-world primary prevention population.
- Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists.
- Beyond Weight Loss: Holistic Impacts of a Digital Weight Management Programme Integrating Tirzepatide.
- Innovative Glucagon-like Peptide 1 Receptor Agonists: Exploring the Therapeutic Potential of Specific Modified Monomer, Dimer, and Tetramer in Type 2 Diabetes Treatment.
- Thyroid Dysfunction Following Tirzepatide Use in a Post-thyroidectomy Patient on Stable Levothyroxine Therapy: A Case Study.
- Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis.
- [The effect of exenatide analogs on hydruretic function of rat kidney under water load].
- Two new doses of dulaglutide (Trulicity) for diabetes.
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
- Liraglutide-Induced Acute Hepatocellular Injury With Positive Rechallenge: A Case Report and Literature Review.
- Dulaglutide slows kidney disease in type 2 diabetes - Author's reply.
- Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series.
- Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
- Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
- [Optimizing treatment of type 2 diabetic patients].
- GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far.
- A commentary on 'Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial'.
- From awareness to action: evolving endocrinologist practices in obesity treatment in Italy.
- [In obese, non-diabetic adults, tirzepatide results in greater weight loss than semaglutide.]
- A review of survodutide: a new dual acting agonist.
- Correction to "Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes".
- Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
- In type 2 diabetes, tirzepatide reduced HbA<sub>1c</sub> vs. semaglutide.
- Semaglutide targets the Isg15-FUNDC1 axis: suppressing IFN-β overactivation and attenuating blood-brain barrier injury in diabetic intracerebral hemorrhage.
- Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue.
- Antidiabetikum vor neuer Karriere.
- In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.
- Retrospective Analysis of Hospitalized Patients with Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide 1 Receptor Agonist Therapy.
- Expanded table: some available insulins for type 2 diabetes.
- Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens.
- Letter to the Editor: Can semaglutide result in a tangible cardiovascular benefit in recipients of liver transplants?
- Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.
- Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.
- MicroRNA-451a downregulation in liraglutide-treated individuals with diabetes: A potential cardiovascular protective mechanism.